Review

cd62l sell (fluidigm)

fluidigm is a verified supplier

fluidigm manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

fluidigm cd62l sell
Both CD161 + and CD161 - ProTcell subsets retain T and NK cell potential as well as thymus seeding ability. (A–E, G, H) ProTcells were produced from CB CD34 + cells in 7 days as indicated in <xref ref-type=

Both CD161 + and CD161 - ProTcell subsets retain T and NK cell potential as well as thymus seeding ability. (A–E, G, H) ProTcells were produced from CB CD34 + cells in 7 days as indicated in <xref ref-type=

cd62l sell - by Bioz Stars, 2026-03

93/100 stars

Images

1) Product Images from "Ex vivo- generated lymphoid progenitors encompass both T cell and innate lymphoid cell fates"

Article Title: Ex vivo- generated lymphoid progenitors encompass both T cell and innate lymphoid cell fates

Journal: Frontiers in Immunology

doi: 10.3389/fimmu.2025.1617707

Figure 1A and sorted by FACS regarding their CD161 expression for further NK or T cell differentiation and functional in vivo experiment. To ensure the consistency, we used the same cell lot and the same sorted cell populations to perform the experiments shown in this figure, including NK cell differentiation, T cell differentiation, and the in vivo engraftment assay. (A) Experimental scheme for CD7 + CD161 - (red frame) and CD7 + CD161 + (green frame) cell subset sorting before NK or T cell differentiation. Differentiating cell phenotype was assessed by flow cytometry. (B, C) CD7 + CD161 +/- lymphoid progenitors were cultured for 14 days in the presence of IL15 without any feeder cell for NK differentiation. Bar plots represent the mean ± SD of (B) the proportion and (C) number of CD56 + NK-primed cells in the culture. (D, E) CD7 + CD161 +/- lymphoid progenitors were co-cultured for 4 weeks with OP9-DLL1 to advance T cell differentiation. Line plots depicting the mean ± SD of the (D) proportion and (E) number of CD3 + developing T cell throughout the culture. *p<0.05 values are for multiple paired Student’s t-test. (F) ProTcells were produced from mPB and CB CD34 + cells and their protein expression (CyTOF) was assessed in a single cell fashion, and restricted to CD7 + progenitors, as described in Figures 1A, B . CyTOF data was visualized by UMAP dimension reduction technic. UMAP projections illustrate the protein expression of several adhesion/homing molecules CCR9, CCR7, CXCR4, CD44, CD62L, SELPLG, ITGA4 and ITGB4. The black line separates the CD161-enriched from the CD161-devoid cells. (G) CD7 + CD161 - or CD7 + CD161 + cell subset has been injected separately into NSG neonates (<4-day-old). T cell reconstitution was analyzed by flow cytometry in the thymus at 6-week-post-transplantation. Bar plot representing the human chimerism (human CD45 + cells/human + murine CD45 + cells) and (H) the proportion of mature CD3 + TCRαβ + T cells in the thymus of mice injected either CD161 + or CD161 - ProTcells. ns, non significant for (B, C) Wilcoxon signed-rank test, (D) multiple paired Student's t-test, (G, H) Mann-Whitney U test. " title="... of several adhesion/homing molecules CCR9, CCR7, CXCR4, CD44, CD62L, SELPLG, ITGA4 and ITGB4. The black line separates ..." property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet: Both CD161 + and CD161 - ProTcell subsets retain T and NK cell potential as well as thymus seeding ability. (A–E, G, H) ProTcells were produced from CB CD34 + cells in 7 days as indicated in Figure 1A and sorted by FACS regarding their CD161 expression for further NK or T cell differentiation and functional in vivo experiment. To ensure the consistency, we used the same cell lot and the same sorted cell populations to perform the experiments shown in this figure, including NK cell differentiation, T cell differentiation, and the in vivo engraftment assay. (A) Experimental scheme for CD7 + CD161 - (red frame) and CD7 + CD161 + (green frame) cell subset sorting before NK or T cell differentiation. Differentiating cell phenotype was assessed by flow cytometry. (B, C) CD7 + CD161 +/- lymphoid progenitors were cultured for 14 days in the presence of IL15 without any feeder cell for NK differentiation. Bar plots represent the mean ± SD of (B) the proportion and (C) number of CD56 + NK-primed cells in the culture. (D, E) CD7 + CD161 +/- lymphoid progenitors were co-cultured for 4 weeks with OP9-DLL1 to advance T cell differentiation. Line plots depicting the mean ± SD of the (D) proportion and (E) number of CD3 + developing T cell throughout the culture. *p<0.05 values are for multiple paired Student’s t-test. (F) ProTcells were produced from mPB and CB CD34 + cells and their protein expression (CyTOF) was assessed in a single cell fashion, and restricted to CD7 + progenitors, as described in Figures 1A, B . CyTOF data was visualized by UMAP dimension reduction technic. UMAP projections illustrate the protein expression of several adhesion/homing molecules CCR9, CCR7, CXCR4, CD44, CD62L, SELPLG, ITGA4 and ITGB4. The black line separates the CD161-enriched from the CD161-devoid cells. (G) CD7 + CD161 - or CD7 + CD161 + cell subset has been injected separately into NSG neonates (<4-day-old). T cell reconstitution was analyzed by flow cytometry in the thymus at 6-week-post-transplantation. Bar plot representing the human chimerism (human CD45 + cells/human + murine CD45 + cells) and (H) the proportion of mature CD3 + TCRαβ + T cells in the thymus of mice injected either CD161 + or CD161 - ProTcells. ns, non significant for (B, C) Wilcoxon signed-rank test, (D) multiple paired Student's t-test, (G, H) Mann-Whitney U test.

Techniques Used: Produced, Expressing, Cell Differentiation, Functional Assay, In Vivo, Flow Cytometry, Cell Culture, Injection, Transplantation Assay, MANN-WHITNEY

Image Search Results

a CCR7, CXCR5, and CD62L expression levels (% and geometric mean fluorescence intensity (GMFI)) on ex vivo expanded human NK cells 6 hours after electroporation with one or several mRNAs ( n = 10). b Transwell migration of Sham (no mRNA) or mRNA-electroporated human NK cells against gradients of one or several of the following chemokines: CCL19 (CCR7 ligand), CCL21 (CCR7 ligand), CXCL13 (CXCR5 ligand) and CXCL12 (CXCR4 ligand) ( n = 6–10). Bars, mean. Error bars, SEM. The Wilcoxon matched‐pairs signed‐rank test comparing mRNA-electroporated vs sham-electroporated NK cells was used for statistics.

Journal: NPJ Precision Oncology

Article Title: Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity

doi: 10.1038/s41698-024-00595-w

Figure Lengend Snippet: a CCR7, CXCR5, and CD62L expression levels (% and geometric mean fluorescence intensity (GMFI)) on ex vivo expanded human NK cells 6 hours after electroporation with one or several mRNAs ( n = 10). b Transwell migration of Sham (no mRNA) or mRNA-electroporated human NK cells against gradients of one or several of the following chemokines: CCL19 (CCR7 ligand), CCL21 (CCR7 ligand), CXCL13 (CXCR5 ligand) and CXCL12 (CXCR4 ligand) ( n = 6–10). Bars, mean. Error bars, SEM. The Wilcoxon matched‐pairs signed‐rank test comparing mRNA-electroporated vs sham-electroporated NK cells was used for statistics.

Article Snippet: Custom-made mRNAs encoding for human CCR7 and CXCR5 were obtained from TriLink Biotechnologies. mRNAs encoding for human CD62L and mouse CCR7, CXCR5, and CD62L were prepared from plasmids purchased from SinoBiological: (human CD62L (HG11838-UT), mouse CCR7 (MG50873-UT), mouse CXCR5 (MG50843-UT), mouse CD62L (MG50045-UT)) using the HiScribe T7 ARCA mRNA Kit (with tailing) and the MEGAclear™ Kit (Invitrogen) according to the manufacturer’s instructions.

Techniques: Expressing, Fluorescence, Ex Vivo, Electroporation, Migration

a Experimental layout for in vivo homing of adoptively infused expanded human NK cells electroporated with mRNAs coding for the mouse CCR7, CXCR5. and CD62L molecules. Created with BioRender.com. b Dot plots (pooled mice for each condition) for NK cell LN homing comparing Sham vs Ccr7/Cxcr5/Cd62L mRNA conditions and assessment of NK cell number in LNs by flow cytometry, calculated out of the total live cells ( n = 9 mice). c In vivo homing of ex vivo expanded human NK cells in several organs 18–20 hours after cell transfer into SCID/Beige mice as assessed by flow cytometry, comparing Sham vs Ccr7/Cxcr5/Cd62L mRNA conditions ( n = 9 mice). d In vivo homing of ex vivo expanded human NK cells in LNs after mRNA electroporation coding for one or several molecules compared to Sham (no mRNA) ( n = 3–6 mice) and dot plots (pooled mice for each condition) for NK cell homing comparing all mRNA conditions. Bars, mean. Error bars, SEM. The Mann–Whitney U test comparing mRNA-electroporated vs sham-electroporated NK cells was used for statistics.

Journal: NPJ Precision Oncology

Article Title: Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity

doi: 10.1038/s41698-024-00595-w

Figure Lengend Snippet: a Experimental layout for in vivo homing of adoptively infused expanded human NK cells electroporated with mRNAs coding for the mouse CCR7, CXCR5. and CD62L molecules. Created with BioRender.com. b Dot plots (pooled mice for each condition) for NK cell LN homing comparing Sham vs Ccr7/Cxcr5/Cd62L mRNA conditions and assessment of NK cell number in LNs by flow cytometry, calculated out of the total live cells ( n = 9 mice). c In vivo homing of ex vivo expanded human NK cells in several organs 18–20 hours after cell transfer into SCID/Beige mice as assessed by flow cytometry, comparing Sham vs Ccr7/Cxcr5/Cd62L mRNA conditions ( n = 9 mice). d In vivo homing of ex vivo expanded human NK cells in LNs after mRNA electroporation coding for one or several molecules compared to Sham (no mRNA) ( n = 3–6 mice) and dot plots (pooled mice for each condition) for NK cell homing comparing all mRNA conditions. Bars, mean. Error bars, SEM. The Mann–Whitney U test comparing mRNA-electroporated vs sham-electroporated NK cells was used for statistics.

Techniques: In Vivo, Flow Cytometry, Ex Vivo, Electroporation, MANN-WHITNEY

a Ex vivo expansion and b degranulation capacity of NK cells from PB of patients with FL and healthy donors ( n = 6). c Transwell migration of Sham (no mRNA) and hCCR7 mRNA-modified NK cells against gradients of CCL19 6-8 hours after electroporation ( n = 6). d Viability and expression kinetics of CCR7, CXCR5, CD62L, and CD16 molecules on ex vivo expanded human NK cells from FL patients after mRNA electroporation compared to Sham (no mRNA) ( n = 2). e Transwell migration of Sham (no mRNA) and mRNA-electroporated NK cells from two FL patients against gradients of one or several chemokines 6–8 hours after electroporation. f Degranulation capacity of NK cells from two patients with FL against different target cell lines 24 hours after mRNA electroporation compared to Sham (no mRNA). g Representative example of degranulation capacity of ex vivo expanded human NK cells from a lymphoma patient against autologous LN fine-needle biopsy material containing primary tumor cells after electroporation with Sham, CCR7, CXCR5, CD62L or additionally CD16-158V mRNA. The Mann-Whitney U test was used for statistics in a and b .

Journal: NPJ Precision Oncology

Article Title: Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity

doi: 10.1038/s41698-024-00595-w

Figure Lengend Snippet: a Ex vivo expansion and b degranulation capacity of NK cells from PB of patients with FL and healthy donors ( n = 6). c Transwell migration of Sham (no mRNA) and hCCR7 mRNA-modified NK cells against gradients of CCL19 6-8 hours after electroporation ( n = 6). d Viability and expression kinetics of CCR7, CXCR5, CD62L, and CD16 molecules on ex vivo expanded human NK cells from FL patients after mRNA electroporation compared to Sham (no mRNA) ( n = 2). e Transwell migration of Sham (no mRNA) and mRNA-electroporated NK cells from two FL patients against gradients of one or several chemokines 6–8 hours after electroporation. f Degranulation capacity of NK cells from two patients with FL against different target cell lines 24 hours after mRNA electroporation compared to Sham (no mRNA). g Representative example of degranulation capacity of ex vivo expanded human NK cells from a lymphoma patient against autologous LN fine-needle biopsy material containing primary tumor cells after electroporation with Sham, CCR7, CXCR5, CD62L or additionally CD16-158V mRNA. The Mann-Whitney U test was used for statistics in a and b .

Techniques: Ex Vivo, Migration, Modification, Electroporation, Expressing, MANN-WHITNEY

T cell development in WT and lamp2 KO thymic grafts. Representative dot plots of CD4 and CD8 expression within (A) total thymocytes and (B) TCRB + thymocytes in thymic grafts of Nude recipients transplanted with WT (WT-Nu) and lamp2 KO ( lamp2 KO-Nu) ectopic thymus, 8–10 weeks after transplantation. Numbers on the plots indicate the frequencies of the different subsets. Bar graphs in A and B depict the average absolute cellularity of the thymus and the indicated thymocyte subsets in WT-Nu (gray) and lamp2 KO-Nu (blue). In B, ratio of the frequency of SP4:SP8 is shown in WT-Nu and lamp2 KO-Nu, as well in the endogenous thymus. (C) Analysis of peripheral T cells in spleens from WT-Nu and lamp2 KO-Nu mice. Graphs (left) represent the average % and numbers of TCRB + T cells in the spleen. Dot plots show CD44 and SELL/CD62L expression within CD4 and CD8 T cells. Graphs (right) show average cellularity of naïve (SELL/CD62L + CD44 lo ) and effector/memory (SELL/CD62L ± CD44 hi ) CD4 and CD8 T cells. Data represent an average of 3 independent experiments (n = 10 WT and lamp2 KO ectopic thymi). Results in A-C are shown as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001.

Journal: Autophagy

Article Title: LAMP2 regulates autophagy in the thymic epithelium and thymic stroma-dependent CD4 T cell development

doi: 10.1080/15548627.2022.2074105

Figure Lengend Snippet: T cell development in WT and lamp2 KO thymic grafts. Representative dot plots of CD4 and CD8 expression within (A) total thymocytes and (B) TCRB + thymocytes in thymic grafts of Nude recipients transplanted with WT (WT-Nu) and lamp2 KO ( lamp2 KO-Nu) ectopic thymus, 8–10 weeks after transplantation. Numbers on the plots indicate the frequencies of the different subsets. Bar graphs in A and B depict the average absolute cellularity of the thymus and the indicated thymocyte subsets in WT-Nu (gray) and lamp2 KO-Nu (blue). In B, ratio of the frequency of SP4:SP8 is shown in WT-Nu and lamp2 KO-Nu, as well in the endogenous thymus. (C) Analysis of peripheral T cells in spleens from WT-Nu and lamp2 KO-Nu mice. Graphs (left) represent the average % and numbers of TCRB + T cells in the spleen. Dot plots show CD44 and SELL/CD62L expression within CD4 and CD8 T cells. Graphs (right) show average cellularity of naïve (SELL/CD62L + CD44 lo ) and effector/memory (SELL/CD62L ± CD44 hi ) CD4 and CD8 T cells. Data represent an average of 3 independent experiments (n = 10 WT and lamp2 KO ectopic thymi). Results in A-C are shown as mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Cell suspensions were stained as described [ ] with Alexa Fluor 488/FITC-conjugated anti-CD8A (clone 53–6.7; eBioscience, 11–0081-82), anti-CD44 (clone IM7; Biolegend, 103,022), anti-15G4 (Santa Cruz Biotechnology, sc-53,946), anti-CD5 (clone 53–7.3; Biolegend, 100,605), anti-PECAM1/CD31 (clone MEC13.3; Biolegend, 102,514) and anti-CCL21 (clone 59,106; R&D Systems, IC457G-100UG); PE-conjugated anti-CD4 (clone GK1.5; eBioscience, 12–0041-82), anti-SELL/CD62L (clone MEL-14; eBioscience, 12–0621-81), anti-TCRB (clone H57-597; eBioscience, 12–5961-82), anti-CD80 (clone 16–10A1; eBioscience, 12–0801-82), anti-ENPEP/LY51 (clone 6C3; eBioscience, 12–5891-82), anti-LAMP2 (clone M3/84; Biolegend, 108,505), anti-CD40 (clone 3/23; BD Pharmingen, 553,791) and anti-MHCI Db (clone 28–14-8; eBioscience, 12–5999-82); PerCP-Cy5.5-conjugated anti-PTPRC/CD45.2 (clone 104; Biolegend, 109,828), anti-TCRB (clone H57-597; eBioscience, 45–5961-80) and anti-MHCI Kb (clone AF6-88.5; Biolegend, 116,515); PerCP-eFluor710 anti-CD4 (clone GK1.5; eBioscience, 46–0041, 82); PE-Cy7-conjugated anti-IL2R/CD25 (clone PC.61.5; eBioscience, 25–0251-82) and anti-CD69 (clone H1.2F3; eBioscience, 25–0691-81); APC/eFluor660-conjugated anti-CD8 (clone 53–6.7; eBioscience, 50–0081-82), anti-CD80 (clone 16–10A1; eBioscience, 17–0801-82), anti-EPCAM (clone G8.8; Biolegend, 118,212), anti-CD40 (clone 1C10; eBioscience, 17–0401-81) and anti-CD74 (In1/CD74, Biolegend, 151,003); APC-eFluor780-conjugated anti-I-A/I-E (clone M5/114-15-2; eBioscience, 47–5321-82); eFluor450-conjugated anti-CD24 (clone M1/69; eBioscience, 48–0242-82); BV421 conjugated anti-EPCAM (clone G8.8; Biolegend, 118,225) and anti-CD69 (clone H1.2F3; Biolegend, 104,527); BV510 conjugated anti-CD24 (clone M1/69; Biolegend, 101,831); BV605 conjugated anti-SELL/CD62L (clone MEL-14; Biolegend, 104,437); anti-PDGFRA (clone APA5; Biolegend, 135,916); BV650 conjugated anti-CD80 (clone 16–10A1; Biolegend, 104,731) and anti-CD8A/CD8α (clone 53–6.7; Biolegend, 100,741); BV785 conjugated anti-CD4 (clone GK1.5; Biolegend, 100,453).

Techniques: Expressing, Transplantation Assay

Journal: Frontiers in Immunology

Article Title: Ex vivo- generated lymphoid progenitors encompass both T cell and innate lymphoid cell fates

doi: 10.3389/fimmu.2025.1617707

Figure Lengend Snippet: Both CD161 + and CD161 - ProTcell subsets retain T and NK cell potential as well as thymus seeding ability. (A–E, G, H) ProTcells were produced from CB CD34 + cells in 7 days as indicated in Figure 1A and sorted by FACS regarding their CD161 expression for further NK or T cell differentiation and functional in vivo experiment. To ensure the consistency, we used the same cell lot and the same sorted cell populations to perform the experiments shown in this figure, including NK cell differentiation, T cell differentiation, and the in vivo engraftment assay. (A) Experimental scheme for CD7 + CD161 - (red frame) and CD7 + CD161 + (green frame) cell subset sorting before NK or T cell differentiation. Differentiating cell phenotype was assessed by flow cytometry. (B, C) CD7 + CD161 +/- lymphoid progenitors were cultured for 14 days in the presence of IL15 without any feeder cell for NK differentiation. Bar plots represent the mean ± SD of (B) the proportion and (C) number of CD56 + NK-primed cells in the culture. (D, E) CD7 + CD161 +/- lymphoid progenitors were co-cultured for 4 weeks with OP9-DLL1 to advance T cell differentiation. Line plots depicting the mean ± SD of the (D) proportion and (E) number of CD3 + developing T cell throughout the culture. *p<0.05 values are for multiple paired Student’s t-test. (F) ProTcells were produced from mPB and CB CD34 + cells and their protein expression (CyTOF) was assessed in a single cell fashion, and restricted to CD7 + progenitors, as described in Figures 1A, B . CyTOF data was visualized by UMAP dimension reduction technic. UMAP projections illustrate the protein expression of several adhesion/homing molecules CCR9, CCR7, CXCR4, CD44, CD62L, SELPLG, ITGA4 and ITGB4. The black line separates the CD161-enriched from the CD161-devoid cells. (G) CD7 + CD161 - or CD7 + CD161 + cell subset has been injected separately into NSG neonates (<4-day-old). T cell reconstitution was analyzed by flow cytometry in the thymus at 6-week-post-transplantation. Bar plot representing the human chimerism (human CD45 + cells/human + murine CD45 + cells) and (H) the proportion of mature CD3 + TCRαβ + T cells in the thymus of mice injected either CD161 + or CD161 - ProTcells. ns, non significant for (B, C) Wilcoxon signed-rank test, (D) multiple paired Student's t-test, (G, H) Mann-Whitney U test.

Article Snippet: 153Eu , CD62L (SELL) , Fluidigm , DREG-56 , 3153004C.

Techniques: Produced, Expressing, Cell Differentiation, Functional Assay, In Vivo, Flow Cytometry, Cell Culture, Injection, Transplantation Assay, MANN-WHITNEY

ASNS shapes the immune landscapes in metastatic TdLN and primary tumor site. Figure A-C . LN metastasis model was conducted on C57BL/6 mice with LLC-ASNS WT (n=6), ASNS C2A overexpression cells(n=6) and control group(n=6), primary tumor and popliteal lymph nodes were isolated at the end of the experiment, and primary tumor volume(B) and TdLN volume/tumor volume(C) was measured and analyzed. 5D-F . (D) Representative FACS profiles of CD8+T cells are shown. The percentage(E) and number(F) of CD8+ subset in TIL cells isolated from primary tumor is shown. 5G-I . (G) Representative FACS profiles of the co-expression pattern of CD44 and CD62L, or the co-expression pattern of TCF-1and TOX in CD8+ T cells are shown. The number(H) and percentage(I) of CD44+, CD44+CD62L+, CD44+CD62L-, Tsl and TTSM subset in CD8+T cells isolated from TdLN is shown. 5J-L . (J) Representative FACS profiles of the co-expression pattern of CD44 and CD62L, or the co-expression pattern of TCF-1and TOX in CD8+ T cells are shown. The number(K) and percentage(L) of CD44+, CD44+CD62L+, CD44+CD62L-, Tsl and TTSM subset in CD8+T cells isolated from primary tumor is shown.

Journal: International Journal of Biological Sciences

Article Title: Lung Cancer Cell-intrinsic Asparagine Synthetase Potentiates Anti-Tumor Immunity via Modulating Immunogenicity and Facilitating Immune Remodeling in Metastatic Tumor-draining Lymph Nodes

doi: 10.7150/ijbs.114791

Figure Lengend Snippet: ASNS shapes the immune landscapes in metastatic TdLN and primary tumor site. Figure A-C . LN metastasis model was conducted on C57BL/6 mice with LLC-ASNS WT (n=6), ASNS C2A overexpression cells(n=6) and control group(n=6), primary tumor and popliteal lymph nodes were isolated at the end of the experiment, and primary tumor volume(B) and TdLN volume/tumor volume(C) was measured and analyzed. 5D-F . (D) Representative FACS profiles of CD8+T cells are shown. The percentage(E) and number(F) of CD8+ subset in TIL cells isolated from primary tumor is shown. 5G-I . (G) Representative FACS profiles of the co-expression pattern of CD44 and CD62L, or the co-expression pattern of TCF-1and TOX in CD8+ T cells are shown. The number(H) and percentage(I) of CD44+, CD44+CD62L+, CD44+CD62L-, Tsl and TTSM subset in CD8+T cells isolated from TdLN is shown. 5J-L . (J) Representative FACS profiles of the co-expression pattern of CD44 and CD62L, or the co-expression pattern of TCF-1and TOX in CD8+ T cells are shown. The number(K) and percentage(L) of CD44+, CD44+CD62L+, CD44+CD62L-, Tsl and TTSM subset in CD8+T cells isolated from primary tumor is shown.

Article Snippet: For mIHC, the mouse tissue slides were sequentially labeled with monoclonal antibodies against CD44 (Bosterbio, A00052), CD62L (Bosterbio, PB9389), CD8 (Bosterbio, A02236-1), Ovabumin (Abcam, ab181688), and TCF-1 (Cell Signaling Technology, 2203T).

Techniques: Over Expression, Control, Isolation, Expressing

ASNS-high-expression metastases generated lymphocyte niches enriched with activated T cells, memory T cells, Tsl and TTSM. Figure A-C . Representative immunofluorescence staining images of metastatic TdLNs from LN metastasis model. 6D . The number of CD8+ T cells in the metastasis locations within TdLNs (ASNS WT , n=6, ASNS C2A , n=5, and EV, n=4). 6E-F . The number(E) and percentage(F) of CD44+CD8+T cells among all CD8 T cells in the metastasis locations within TdLNs (ASNS WT , n=6, ASNS C2A , n=5, and EV, n=4). 6G-H . The number(G) and percentage(H) of Tsl cells among all CD8 T cells in the metastasis locations within TdLNs (ASNS WT , n=6, ASNS C2A , n=5, and EV, n=4). 6I-J . The number(I) and percentage(J) of TTSM cells among all CD8 T cells in the metastasis locations within TdLNs (ASNS WT , n=5, ASNS C2A , n=4, and EV, n=3). 6K . Quantitative estimates of the distance from ova+ to CD8+CD44+CD62L+TCF+(TTSM) (ASNS WT , n=6, ASNS C2A , n=5, and EV, n=4). 6L-M . Representative immunofluorescence staining images of metastatic TdLNs from NSCLC patients. 6N-O . The number(C) and percentage(D) of CD8+ T cells in the metastasis locations within TdLNs(ASNS high group, n=7, and ASNS low group, n=6). 6P-Q . The number (E) and percentage(F) of CD45RO+CD8+ T cells in CD8+T cells in the metastasis locations within TdLNs(ASNS high group, n=7, and ASNS low group, n=6). 6R-S . The number (G) and percentage(H) of Tsl cells in CD8+T cells in the metastasis locations within TdLNs(ASNS high group, n=7, and ASNS low group, n=6). 6T-U . The number (I) and percentage(J) of TTSM cells in CD8+T cells in the metastasis locations within TdLNs(ASNS high group, n=7, and ASNS low group, n=6).

Journal: International Journal of Biological Sciences

doi: 10.7150/ijbs.114791

Figure Lengend Snippet: ASNS-high-expression metastases generated lymphocyte niches enriched with activated T cells, memory T cells, Tsl and TTSM. Figure A-C . Representative immunofluorescence staining images of metastatic TdLNs from LN metastasis model. 6D . The number of CD8+ T cells in the metastasis locations within TdLNs (ASNS WT , n=6, ASNS C2A , n=5, and EV, n=4). 6E-F . The number(E) and percentage(F) of CD44+CD8+T cells among all CD8 T cells in the metastasis locations within TdLNs (ASNS WT , n=6, ASNS C2A , n=5, and EV, n=4). 6G-H . The number(G) and percentage(H) of Tsl cells among all CD8 T cells in the metastasis locations within TdLNs (ASNS WT , n=6, ASNS C2A , n=5, and EV, n=4). 6I-J . The number(I) and percentage(J) of TTSM cells among all CD8 T cells in the metastasis locations within TdLNs (ASNS WT , n=5, ASNS C2A , n=4, and EV, n=3). 6K . Quantitative estimates of the distance from ova+ to CD8+CD44+CD62L+TCF+(TTSM) (ASNS WT , n=6, ASNS C2A , n=5, and EV, n=4). 6L-M . Representative immunofluorescence staining images of metastatic TdLNs from NSCLC patients. 6N-O . The number(C) and percentage(D) of CD8+ T cells in the metastasis locations within TdLNs(ASNS high group, n=7, and ASNS low group, n=6). 6P-Q . The number (E) and percentage(F) of CD45RO+CD8+ T cells in CD8+T cells in the metastasis locations within TdLNs(ASNS high group, n=7, and ASNS low group, n=6). 6R-S . The number (G) and percentage(H) of Tsl cells in CD8+T cells in the metastasis locations within TdLNs(ASNS high group, n=7, and ASNS low group, n=6). 6T-U . The number (I) and percentage(J) of TTSM cells in CD8+T cells in the metastasis locations within TdLNs(ASNS high group, n=7, and ASNS low group, n=6).

Techniques: Expressing, Generated, Immunofluorescence, Staining

Journal: NPJ Precision Oncology

Article Title: Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity

doi: 10.1038/s41698-024-00595-w

Techniques: Expressing, Fluorescence, Ex Vivo, Electroporation, Migration

Journal: NPJ Precision Oncology

Article Title: Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity

doi: 10.1038/s41698-024-00595-w

Techniques: In Vivo, Flow Cytometry, Ex Vivo, Electroporation, MANN-WHITNEY

Journal: NPJ Precision Oncology

Article Title: Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity

doi: 10.1038/s41698-024-00595-w

Techniques: Ex Vivo, Migration, Modification, Electroporation, Expressing, MANN-WHITNEY

Review

Structured Review

Images

1) Product Images from "Ex vivo- generated lymphoid progenitors encompass both T cell and innate lymphoid cell fates"

Similar Products

Image Search Results